What is my likelihood of having axial spondyloarthritis (SpA) with HLA‑B27 positivity and low back pain with stiffness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of Axial Spondyloarthritis with HLA-B27 Positivity and Lower Back Pain with Stiffness

If you have HLA-B27 positivity combined with chronic lower back pain and stiffness, your likelihood of having axial spondyloarthritis is approximately 30-40%, meaning roughly 1 in 3 people with your presentation will have the disease. 1, 2

Your Specific Risk Profile

Post-Test Probability

  • HLA-B27 positivity alone in the context of chronic back pain gives you a 32% post-test probability of having axial SpA 1
  • This translates to a practical reality: only 3 patients with chronic back pain who are HLA-B27 positive need to be evaluated by a rheumatologist to diagnose 1 case of axial SpA 1, 2
  • Your relative risk is increased 20-fold compared to HLA-B27 negative individuals with back pain 3

Key Statistical Parameters

  • Sensitivity of HLA-B27: 90% (meaning only 10% of axial SpA patients are HLA-B27 negative) 1
  • Likelihood ratio: 9, which is considered excellent for a screening test 1
  • Among HLA-B27 positive blood donors with inflammatory symptoms, 13.6% had spondyloarthritis compared to only 0.7% of HLA-B27 negative individuals 3

Critical Features That Increase Your Likelihood Further

Inflammatory Back Pain Characteristics

Your risk increases substantially if your back pain has these features:

  • Morning stiffness lasting >30 minutes 1, 2
  • Pain at night or early morning that wakes you 1
  • Improvement with exercise but not rest 1, 4
  • Alternating buttock pain 4
  • Good response to NSAIDs (improvement within 48 hours) 5
  • Insidious onset before age 45 1, 4

If you have inflammatory back pain PLUS HLA-B27 positivity, your likelihood increases even further, though this combination reduces sensitivity to 68% (meaning more patients are missed) 1

Additional Risk Factors

  • Sacroiliitis on imaging: If you have inflammatory back pain and are HLA-B27 positive, there is a 50% likelihood of having sacroiliitis on MRI 3
  • Family history of spondyloarthritis in first-degree relatives increases risk 4
  • Extra-articular manifestations: psoriasis, uveitis, or inflammatory bowel disease 4
  • Peripheral joint symptoms: enthesitis, dactylitis, or arthritis 4

Important Caveats and Pitfalls

Common Misconceptions

  • Normal inflammatory markers (ESR/CRP) do NOT rule out disease - these are elevated in only 50% of axial SpA patients and have poor sensitivity 1, 2
  • Negative X-rays do NOT exclude disease - radiographic sacroiliitis has only 80% sensitivity and specificity 1
  • HLA-B27 negative disease exists - approximately 10% of axial SpA cases are HLA-B27 negative 6, 2

What This Means for You

  • You should be referred to a rheumatologist immediately for further evaluation given your HLA-B27 positivity and chronic back pain with stiffness 1, 2
  • The rheumatologist will likely perform MRI of sacroiliac joints (not recommended for primary screening but appropriate once you're being evaluated) 1
  • Early diagnosis matters because effective treatments are available, and diagnostic delay of several years is common 4

Two-Step Diagnostic Strategy

The most efficient approach for patients like you:

  1. First step: HLA-B27 testing (which you've already done - positive)
  2. Second step: If HLA-B27 negative, look for additional clinical features (improvement with movement, buttock pain, psoriasis) 7

Since you're HLA-B27 positive, you meet criteria for rheumatology referral regardless of other features 7

Progression Risk

  • Among seemingly healthy first-degree relatives of SpA patients who are HLA-B27 positive, 6% developed clinical axial SpA within just 1 year, with 86% of those being HLA-B27 positive 8
  • This underscores that HLA-B27 positivity is the strongest predictor of disease development 8

References

Related Questions

What is the diagnosis and treatment for a 33-year-old female with lower back pain, psoriasis, joint pain, elevated Erythrocyte Sedimentation Rate (ESR), and positive Human Leukocyte Antigen B27 (HLA-B27)?
What are the management and treatment options for individuals who test positive for HLA-B27 (Human Leukocyte Antigen B27)?
What are the management and treatment options for a patient with an HLA (Human Leukocyte Antigen) B27 abnormality, potentially indicating ankylosing spondylitis or other spondyloarthropathies?
Can a previously negative HLA-B27 (Human Leukocyte Antigen B27) test result become positive years later?
What percentage of the general population is HLA-B27 (Human Leukocyte Antigen B27) positive without spine problems?
For a 70‑kg adult with type 2 diabetes who only has regular (short‑acting) insulin available, how should I initiate and titrate the insulin using a twice‑daily schedule and combine it with metformin?
How should acute laryngitis be managed, including symptomatic therapy, NSAIDs, steroids, antibiotics, and red‑flag signs requiring urgent care?
In a patient with type 2 diabetes whose HbA1c decreased from 13 % to 12 % and fasting plasma glucose decreased from 19 mmol/L to 10.6 mmol/L after 5 weeks of metformin 2000 mg daily and dapagliflozin 10 mg daily, is adding gliclazide 30 mg sufficient to achieve glycemic targets?
In an adult with acute cholecystitis pain and no severe psychiatric illness, uncontrolled hypertension, or elevated intracranial pressure, can low‑dose ketamine be used for analgesia, and what dosing and monitoring are recommended?
What are the pre‑anesthetic, intra‑operative, and postoperative considerations for a neonate with Arnold‑Chiari (Chiari II) malformation and myelomeningocele undergoing corrective myelomeningocele surgery under general anesthesia?
For a patient with rheumatic heart disease who has symptomatic heart failure with reduced systolic function or atrial fibrillation requiring rate control, what are the indications, starting dose, titration, monitoring parameters, and contraindications for digoxin therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.